Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04895579Phase 1Completed

Lung Cancer With Copanlisib and Durvalumab

Role: lead

NCT03958045Phase 2Completed

Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma

Role: lead

NCT05245760Phase 2Withdrawn

ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer

Role: lead

All 3 trials loaded